Akili
Akili, which made history last summer by earning regulatory clearance for the first video-game based therapy, now plans to test if its software can help adults suffering from Covid “brain fog.”
Two randomized remote studies, one conducted by Weill Cornell Medicine and New York-Presbyterian Hospital and the other by Vanderbilt University Medical Center, will assess whether AKL-T01, the treatment that Akili commercially markets for ADHD as EndeavorRx, can help improve cognition symptoms in Covid survivors.
The new studies come at a pivotal moment for Akili. EndeavorRx is being prescribed by more doctors, but the company is still hoping for widespread acceptance. As Akili labors to show EndeavorRx works, it’s also looking for new pathways to commercialization.